Qarziba (dinutuximab beta) / Jazz, Apeiron Biologics, BeiGene, Recordati  >>  Phase 1
Welcome,         Profile    Billing    Logout  

6 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Qarziba (dinutuximab beta) / Jazz
2016-002221-11: MiNivAN: A study of new antibody treatments for children with relapsed/refractory neuroblastoma in combination with targeted radiotherapy

Not yet recruiting
1
36
Europe
Dinutuximab beta Apeiron, Opdivo (Nivilumab), mIBG: metaiodobenzylguanidine 131-I, Solution for infusion, Concentrate for solution for infusion, Solution for injection/infusion, Dinutuximab beta Apeiron, Opdivo (Nivilumab), mIBG: metaiodobenzylguanidine 131-I
University Hospital Southampton NHS Foundation Trust, University Hospital Southampton NHS Foundation Trust (UK), Bristol Myers Squibb, Eusa Pharma, Solving Kids Cancer, EUSA Pharma
Neuroblastoma, Neuroblastoma is the most common extra-cranial solid tumour in children, Diseases [C] - Cancer [C04]
 
 
NANT, NCT01711554: Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma

Active, not recruiting
1
27
Canada, US
Dinutuximab, Ch 14.18UTC, Ch14.18, Dinutuximab Beta, MOAB Ch14.18, monoclonal antibody Ch14.18, Qarziba, Unituxin, Isotretinoin, 13-cis retinoic acid, 13-cis-Retinoate, 13-cis-Retinoic Acid, 13-cis-Vitamin A Acid, 13-cRA, Absorica, Accure, Accutane, Amnesteem, cis-Retinoic Acid, Cistane, Claravis, Isotretinoinum, Isotrex, Isotrexin, Myorisan, Neovitamin A, Neovitamin A Acid, Oratane, Retinoicacid-13-cis, Ro 4-3780, Ro-4-3780, Roaccutan, Roaccutane, Roacutan, Sotret, ZENATANE, Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Pharmacological Study
National Cancer Institute (NCI)
Recurrent Neuroblastoma, Refractory Neuroblastoma
09/18
03/25
Inbraced, NCT02914405: Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma

Recruiting
1
44
Europe, US
Nivolumab, BMS-936558, MDX1106, ONO-4538, anti-PD-1) NSC#748726, IND #124729, Ch14.18/CHO, Mouse-human chimeric monoclonal anti-GD2 Immunoglobulin G1 (IgG1) antibody
University Hospital Southampton NHS Foundation Trust, University College London Hospitals, University of Wisconsin, Madison, University Hospital Greifswald, Solving Kids' Cancer US/EU, Joining Against Cancer in Kids, The Band of Parents
Neuroblastoma
09/24
07/25
NCT05373901: Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta as Maintenance Therapy in Chinese Patients With High-risk Neuroblastoma

Completed
1
8
RoW
Dinutuximab Beta, 13 cis retinoic acid
BeiGene
High-risk Neuroblastoma
06/23
06/23
NCT04751383: Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

Active, not recruiting
1
82
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dinutuximab, Ch 14.18UTC, Ch14.18, Dinutuximab Beta, MOAB Ch14.18, monoclonal antibody Ch14.18, Qarziba, Unituxin, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Magrolimab, Hu5F9-G4, ONO-7913, Resection, Surgical Resection
National Cancer Institute (NCI)
High Risk Neuroblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma, Resectable Osteosarcoma
12/32
12/32
ChIm-NB-PL, NCT05272371 / 2021-003832-96: Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease

Recruiting
1
20
Europe
Chemoimmunotherapy (Dinutuximab beta in combination with chemotherapy)
Jagiellonian University, Medicinal Research Agency
High-Risk Neuroblastoma
09/26
12/26

Download Options